In the coming weeks, CDER will publish online a list of surrogate endpoints that led to the approval of oncology drugs and biologicals for the first time, FDA Commissioner Scott Gottlieb announced at the National Comprehensive Cancer Network Policy Summit in Washington, D.C.
Source: Drug Industry Daily